Q-omics provides the consensus-scored CTAG1A profile across patient tissues and cancer cell-line models. CTAG1A expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, CTAG1A is differentially expressed in 1, with the highest sampling consensus in LIHC. Additionally, CTAG1A RNA expression shows 4,800 significant gene co-expression associations, with the highest sampling consensus in BRCA. Together, these results highlight COAD, LIHC, and BRCA as cancer lineages where CTAG1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CTAG1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CTAG1A survival associations across molecular data types. CTAG1A RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CTAG1A RNA expression–survival associations across cancer types. High CTAG1A expression shows unfavorable associations in COAD, THCA, KIRC, DLBC, LIHC and KIRP. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for CTAG1A RNA expression.
This table summarizes CTAG1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for CTAG1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CTAG1A shows higher tumor expression in LIHC. The LIHC box plot shows higher CTAG1A RNA expression in tumor versus normal tissue (log2 FC = +0.013, t-test p = .026).
This table shows molecular features associated with CTAG1A in patient tissues and cancer cell lines. In patient samples, CTAG1A shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, CTAG1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LUNG_SCLC.
